Evopoint Biosciences Inc.

This study tests an experimental drug called XNW5004 in 65 people with follicular lymphoma (a slow-growing blood cancer) that has returned or stopped responding to at least three prior treatments. Participants take the drug twice daily for 28-day cycles. The main goal is to see h…

This study tests a new drug called XNW28012 in people with advanced solid tumors (pancreatic, ovarian, cervical, or colorectal cancers) that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug shri…

This Phase 3 trial tests whether the experimental drug XNW5004 can help people with relapsed or refractory peripheral T-cell lymphoma, a rare and aggressive blood cancer. About 120 participants will receive either XNW5004 or the existing drug chidamide. The main goal is to see if…